Prior Authorization: What Patients Need to Know

Prior authorization is one of the most consequential administrative processes in American healthcare — a gatekeeping mechanism that sits between a physician's prescription pad and a patient's pharmacy counter or operating table. This page explains what prior authorization is, how the approval process unfolds, where it most commonly appears, and what determines whether a request succeeds or fails. Understanding its structure is the first step toward navigating it with less friction.

Definition and scope

A prior authorization (PA) — sometimes called pre-authorization or pre-certification — is a requirement imposed by a health insurer or pharmacy benefit manager that a provider obtain formal approval before a specific drug, procedure, or service will be covered. The insurer is not merely reviewing a claim after the fact; it is inserting itself into the clinical decision before treatment begins.

The scale of this process is substantial. The American Medical Association's 2022 Prior Authorization Physician Survey found that physicians complete an average of 45 prior authorization requests per physician per week, with 88 percent of surveyed physicians describing the burden as "high" or "extremely high." That volume translates directly into delayed care for patients.

Prior authorization applies across commercial insurance, Medicare Advantage plans, and Medicaid managed care. Traditional Medicare (Parts A and B) uses PA requirements in more limited circumstances, but Medicare Advantage plans — which enrolled more than 30 million Americans as of 2023 (CMS Medicare Advantage enrollment data) — apply them broadly.

How it works

The mechanics follow a recognizable sequence, though timelines and documentation requirements vary by insurer and service type.

1. Physician identifies a treatment — a specialist recommends a biologic medication, an MRI, or an elective surgical procedure.
2. PA request submitted — the provider's office contacts the insurer, usually by phone, fax, or an online portal, submitting clinical notes, diagnosis codes, and supporting documentation.
3. Insurer reviews the request — a utilization management team, often staffed by nurses at the initial review stage, evaluates the request against the insurer's coverage criteria.
4. Determination issued — the insurer approves, denies, or requests additional information. Federal rules under the No Surprises Act and CMS regulations require that urgent requests receive a response within 72 hours and standard requests within 7 calendar days.
5. Appeals process activated (if denied) — a denied PA triggers the right to an internal appeal and, in most states, an independent external review.

Peer-to-peer review is a critical but often underused step: a physician on the insurer's panel speaks directly with the treating provider. This conversation frequently reverses initial denials, particularly for specialty medications.

The distinction between prospective authorization (sought before treatment) and retrospective authorization (sought after emergency or urgent care) matters enormously. Retrospective reviews apply different standards and carry different risk of non-payment, making patient advocacy support especially valuable when a patient has already received care and is awaiting coverage confirmation.

Common scenarios

Prior authorization appears most frequently in four clinical areas:

• Specialty pharmaceuticals — biologics for rheumatoid arthritis, inflammatory bowel disease, and oncology are almost universally subject to PA. A single infusion of a biologic can cost $10,000 or more, which concentrates insurer scrutiny.
• Advanced imaging — MRI, CT, and PET scans routinely require PA, particularly when ordered without a preceding X-ray or when the clinical indication falls outside narrow guideline parameters.
• Behavioral health services — residential treatment, intensive outpatient programs, and certain psychotropic medications trigger PA at high rates, creating documented barriers to timely mental health and substance use disorder treatment.
• Surgical procedures — bariatric surgery, joint replacement, and spine surgery are frequent PA targets, with insurers requiring documented failure of conservative treatments before approving operative intervention.

Step therapy — sometimes called "fail first" — deserves specific mention here. Insurers routinely require patients to try and fail a lower-cost treatment before approving the one a physician originally prescribed. A patient whose rheumatologist recommends a specific biologic may be required to try two other medications first, regardless of the physician's clinical reasoning. As described in the key dimensions of patient advocacy, navigating step therapy protocols is one of the most concrete areas where advocacy intervention changes outcomes.

Decision boundaries

Insurers base PA decisions on medical necessity criteria — proprietary clinical guidelines that are not always publicly available and do not always align with specialty society guidelines published by organizations like the American College of Rheumatology or the American Academy of Neurology.

Three factors most consistently determine whether a PA is approved or denied:

Medical necessity documentation. The physician's notes must speak the insurer's language — diagnosis codes must match, clinical findings must be explicit, and prior treatment history must be documented in the record, not merely asserted.

Plan-specific coverage criteria. Each insurer maintains its own coverage determination criteria. A drug approved by the FDA for a specific indication may still be excluded from a particular plan's formulary or subject to step therapy requirements that FDA approval does not preempt.

Appeals history and peer-to-peer engagement. A first denial is not a final answer. The patient advocacy frequently asked questions section addresses the appeals process in detail, but the structural reality is that denial rates at the appeals stage are lower than at initial review — meaning persistence and documentation quality directly affect outcomes.

The CMS finalized a rule in January 2024 requiring that Medicare Advantage, Medicaid, and CHIP insurers provide specific clinical reasons for all PA denials and shorten standard decision timelines to 7 days (CMS Prior Authorization Rule, CMS-0057-F). That rule takes full effect in 2026, but its existence signals the regulatory direction — and reflects the weight of evidence that prior authorization, as currently administered, frequently delays or prevents medically appropriate care.